Form 4: CRISPR Therapeutics Director John Greene Receives Options

Director John Greene was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Summary

• Director John Greene received a grant of 13,000 stock options for CRISPR Therapeutics AG (CRSP).
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are subject to a one-year vesting schedule in 12 equal monthly installments.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Aligns director incentives with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon continued service to the company or its subsidiaries.

Future Outlook

The options vest over a 12-month period ending on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board alignment with corporate performance and retention of key leadership.

Comparison to Industry Standards

• The use of monthly vesting over one year is a standard retention mechanism for board members in mid-cap biotech firms.
• The exercise price reflects the market value at the time of grant, consistent with SEC reporting requirements for non-qualified stock options.

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Trading, Stock Options, Biotech